Shares of Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) have been assigned an average recommendation of "Hold" from the twenty analysts that are presently covering the stock, Marketbeat.com reports. Fourteen investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $11.81.
A number of brokerages recently issued reports on TDOC. Truist Financial decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a "hold" rating for the company in a research note on Friday, August 2nd. TD Cowen reduced their price objective on Teladoc Health from $15.00 to $9.00 and set a "hold" rating for the company in a research note on Thursday, August 1st. Oppenheimer decreased their price objective on Teladoc Health from $21.00 to $17.00 and set an "outperform" rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $10.00 price target on shares of Teladoc Health in a research report on Tuesday, August 20th. Finally, Stifel Nicolaus cut their price objective on shares of Teladoc Health from $16.00 to $9.00 and set a "hold" rating for the company in a research report on Thursday, August 1st.
View Our Latest Stock Report on TDOC
In related news, CEO Laizer Kornwasser sold 10,879 shares of Teladoc Health stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $88,555.06. Following the completion of the transaction, the chief executive officer now owns 99,929 shares in the company, valued at approximately $813,422.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Teladoc Health news, CEO Laizer Kornwasser sold 10,879 shares of the firm's stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $88,555.06. Following the sale, the chief executive officer now owns 99,929 shares in the company, valued at $813,422.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Mala Murthy sold 8,750 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the transaction, the chief financial officer now owns 85,767 shares of the company's stock, valued at approximately $614,091.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,377 shares of company stock worth $438,054 over the last ninety days. 0.95% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its holdings in Teladoc Health by 84.5% during the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider's stock valued at $40,000 after buying an additional 1,854 shares during the last quarter. Creative Planning increased its position in shares of Teladoc Health by 184.7% during the third quarter. Creative Planning now owns 64,125 shares of the health services provider's stock valued at $589,000 after acquiring an additional 41,602 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Teladoc Health in the third quarter worth $409,000. Wedmont Private Capital bought a new stake in Teladoc Health in the 3rd quarter worth about $120,000. Finally, CWM LLC lifted its position in Teladoc Health by 219.1% during the third quarter. CWM LLC now owns 13,557 shares of the health services provider's stock valued at $124,000 after purchasing an additional 9,309 shares during the period. Institutional investors own 76.82% of the company's stock.
Shares of TDOC opened at $9.83 on Friday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -6.97 and a beta of 0.91. Teladoc Health has a 52 week low of $6.76 and a 52 week high of $22.54. The stock's 50-day moving average price is $8.12 and its 200-day moving average price is $10.07. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66.
Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.08. The company had revenue of $642.44 million for the quarter, compared to analysts' expectations of $649.34 million. Teladoc Health had a negative return on equity of 10.25% and a negative net margin of 38.54%. On average, sell-side analysts predict that Teladoc Health will post -1.18 EPS for the current year.
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.